Thursday 19 May 2022 - 03:50
In Business 42 Years - Since 1980
Reminder: Genuine LC Laboratories® brand PMA, which we have been manufacturing in the U.S. for more
than 40 years, is available directly from us: Cat No. P-1680 Phorbol 12-Myristate 13-Acetate, >99.5%.
Our PMA is also available from our >50 U.S. and international distributors, and from more than a dozen
major biochemical reagent "resellers" (who sell our PMA under their own brand names and labels)
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
E-4997 Erlotinib, Free Base, >99%
Synonyms : [CP-358774] [OSI-774] [Ro 50-8231]
Related Terms : [Tarceva]
- Size
- US $
- €
- £
- ¥
- 500 mg
- 37
- 35
- 29
- 4,800
- In stock
- 1 g
- 48
- 45
- 38
- 6,200
- In stock
- 2 g
- 72
- 68
- 58
- 9,300
- In stock
- 5 g
- 136
- 129
- 109
- 17,600
- In stock
- 10 g
- 238
- 226
- 191
- 30,800
- Add to Cart
- Out of stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 393.44
- C22H23N3O4
- [183321-74-6]
- M.I. 14: 3672
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 10 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.
- More than 830 labs worldwide have purchased Erlotinib or its salt forms from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
- This research compound is the free base form of erlotinib. We also offer the hydrochloride salt form of erlotinib: Cat. No. E-4007 Erlotinib, Hydrochloride Salt.
- Related CAS numbers: 248594-19-6 for erlotinib mesylate.
- This erlotinib product is the free base, whose CAS number is given above. The CAS number of the hydrochloride salt is 183319-69-9.
- Erlotinib (as the hydrochloride salt ) is the active ingredient in the drug product sold under the trade name Tarceva®. This drug has been approved in at least one country for use in patients with pancreatic cancer, non-small cell lung cancer and several other types of cancer. NOTE: THE ERLOTINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT TARCEVA®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
